Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T10:45:33.405Z Has data issue: false hasContentIssue false

Vancomycin Use in a Hospital With Vancomycin Restriction

Published online by Cambridge University Press:  02 January 2015

Mary-Claire Roghmann*
Affiliation:
University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, Maryland
Beulah E. Perdue
Affiliation:
University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, Maryland
Louis Polish
Affiliation:
University of Maryland School of Medicine and University of Maryland Medical System, Baltimore, Maryland
*
Maryland Health Care System (BT111), 10 N Greene St, Baltimore, MD 21201

Abstract

We evaluated vancomycin use in a hospital with endemic vancomycin-resistant enterococci and a vancomycin restriction program. Only 68% of vancomycin was prescribed appropriately. Inappropriate use was due primarily to empirical therapy. In the patients with a microbiological diagnosis following empirical therapy, 83% (25/30) had infections due to bacteria sensitive to an appropriate antibiotic other than vancomycin. However, only 60% (15/25) of these patients had their vancomycin orders changed.

Type
Concise Communications
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Shlaes, DM, Gerding, DN, John, JF Jr, Craig, WA, Bornstein, DL, Duncan, RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275291.Google Scholar
2. Hierholzer, WJ, Garner, JS, Adams, AB, Craven, DE, Flemings, DW, Fortenza, SW, et al. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995;16:105113.Google Scholar
3. Morris, JG Jr, Shay, DK, Hebden, JN, McCarter, RJ Jr, Perdue, BE, Jarvis, W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250259.Google Scholar
4. Ena, J, Dick, J, Jones, R, Wenzel, R. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA 1993;269:598602.Google Scholar
5. Boyle, JF, Soumakis, SA, Rendo, A, Harrington, JA, Gianarkis, DG, Thurberg, BE, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:12801285.Google Scholar
6. Frieden, TR, Munsiff, SS, Low, DE, Willey, BM, Williams, G, Faur, Y, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:7679.Google Scholar
7. Rai, M, Bobek, M, Capozzi, D, Lee, P, Goblman, M, Longworth, M, et al. Vancomycin use in a tertiary care referrai center: compliance with CDC recommendations for preventing the spread of vancomycin resistance. Presented at the annual meeting of the Infectious Disease Society of America; September 1996; New Orleans, LA Abstract 296.Google Scholar
8. Lipsky, B, Baker, C. Improving the appropriateness of vancomycin use in a VA medical center. Presented at the annual meeting of the Infectious Disease Society of America; September 1996; New Orleans, LA Abstract 296.Google Scholar
9. Evans, ME, Kortas, KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996;17:356359.Google Scholar
10. Wilson, WR, Karchmer, AW, Dajani, AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995;274:17061713.Google Scholar